| Document |
Document Title |
|
WO/2017/067881A1 |
The present invention relates to compounds of Formula (I) having pharmacological activity, processes for its preparation, pharmaceutical compositions and their use in the treatment of certain parasitic certain parasiticprotozoalinfection...
|
|
WO/2017/069601A1 |
The present invention relates to novel aminoalkylazoles acting as inhibitors of malarial protease plasmepsin II. These can be used as medicines or as constituent of medicines for the treatment of malaria infection.
|
|
WO/2017/069154A1 |
This pest control agent includes the compound represented by formula (1) or a salt thereof (in the formula: Z represents an oxygen or sulfur atom; B is represented by formula (B-1) when A is represented by formula (A-1); B is represented...
|
|
WO/2017/064558A1 |
The present invention pertains to an immunostimulant comprising (S)-N-(4-amino-5-(quinolin-3-yl)-6,7,8,9-tetrahydropyrimido[
5,4-b]indolizin-8-yl)acrylamide represented by formula (I) or salt thereof, and a pharmaceutical composition for...
|
|
WO/2017/065228A1 |
The present invention provides: a compound represented by formula (I) [wherein A1 represents a nitrogen atom or CR4; R4 represents a hydrogen atom or the like; R1 represents a C2-C10 linear hydrocarbon group having at least one halogen a...
|
|
WO/2017/063017A1 |
Method and use and of an extracted plant based compound of genus Terminalia (particularly, T. ferdinandiana ) in the preparation of a medicament which inhibits and/or blocks the growth of gastrointestinal parasites of the genus Giardia (...
|
|
WO/2017/065183A1 |
The present invention addresses the problem of developing and providing a new agricultural and horticultural insecticide from factors such as the occurrence of pests resistant to existing drugs, since damage due to pests or the like rema...
|
|
WO/2017/060641A1 |
The present invention relates to the use of a veterinary composition comprising a compound of the neonicotinoid family and a compound of the pyrethrinoid family for sandfly control and/or for leishmaniosis control in non-human mammals.
|
|
WO/2017/061497A1 |
Since damage due to harmful insects and the like remains significant in the production of agricultural or horticultural crops, the present invention provides a condensed heterocyclic compound or salts thereof, said compound being a new i...
|
|
WO/2017/055925A2 |
Pharmaceutical compositions and methods for the treatment of malaria are presented. Such compositions and methods may target energy-sensing pathways of the malaria parasite, Plasmoclium, of parasite host cell, or both. The compositions, ...
|
|
WO/2017/057119A1 |
The pyrimidine compound represented in formula (1) is effective as a pest control agent.
|
|
WO/2017/055306A1 |
A series of substituted pyrido[3,2-d]pyrimidine and 1,5-naphthyridine derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment ...
|
|
WO/2017/057120A1 |
The pyrimidine compound represented in formula (1) is effective as a pest control agent.
|
|
WO/2017/057121A1 |
The pyrimidine compound represented in formula (1) is effective as a pest control agent.
|
|
WO/2017/055305A1 |
A series of substituted pyrazolo[1,5-a]pyrimidine and pyrazolo[1,5-a][1,3,5]- triazine derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase ΙΙΙβ (ΡI4ΚΙΙΙβ) activity, are ben...
|
|
WO/2017/052359A1 |
There is herein disclosed a compound of formula I: or a salt solvate or pharmaceutically acceptable derivative thereof, wherein R1 to R7 is as defined herein for use in the treatment of angenogenis and related conditions.
|
|
WO/2017/053851A1 |
Compositions and methods for modified dendrimer nanoparticle ("MDNP") delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive pro...
|
|
WO/2017/053593A1 |
The present disclosure describes a composition and method for treating and preventing malaria. The disclosure describes a peroxybioflavonoid composition comprising an artemisinin compound and one or more bioflavonoid compounds.
|
|
WO/2017/046598A1 |
The present invention relates to a VEGF receptor agonist for use in the treatment of an acute inflammatory disorder associated with the overproduction of pro-inflammatory cytokine, administered with an agent that induces the synthesis of...
|
|
WO/2017/046778A1 |
The present invention discloses the antileishmanial role of Withaferin-A that can be used alone or in combination with existing antileishmanial drugs like Miltefosine to enhance the efficacy of the existed drug through the synergistic ef...
|
|
WO/2017/048689A1 |
Described herein are multilayer films that include modified polypeptide epitopes from Plasmodium falciparum, specifically a modified T* epitope. The multilayer films are capable of eliciting an immune response in a host upon administrati...
|
|
WO/2017/046433A1 |
The invention relates to metal nanoparticles, preferably gold and silver, stabilised with dendrons, having a carbosilane structure and functionalised on the periphery thereof with anionic or cationic groups that provide the nanoparticle ...
|
|
WO/2017/041720A1 |
Disclosed are a mevalonate pathway inhibitor as a vaccine adjuvant, and use thereof. Specifically, the inhibitor is an acetoacetyl-CoA transferase inhibitor, an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, a mevalonate kin...
|
|
WO/2017/040742A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2017/033162A1 |
The present disclosure relates to the field of pharmaceutical chemistry and biotechnology. The present disclosure also relates to a compound of Formula I and a process of preparation thereof. The disclosure furthermore relates to methods...
|
|
WO/2017/030443A1 |
Composition for treatment of mucus on fish gills for a therapeutic or a prophylactic treatment of an amoebic gill disease in fish, where the composition comprises an ex- truded fish feed supplemented with arginlne; said fish feed compris...
|
|
WO/2017/025416A1 |
A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosom...
|
|
WO/2017/026384A1 |
The present invention addresses the problem of developing and providing a novel agricultural and horticultural insecticide due to factors such as the development of pests resistant to existing chemicals since damage by pests is still a m...
|
|
WO/2017/020944A1 |
The present invention concerns novel fused pyrimidinone and triazinone derivatives of formula (I), their process of preparation and their use as antifungal or antiparasitic agents.
|
|
WO/2017/021992A1 |
The present invention relates to salts of anthelmintic compounds with a benzimidazolic structure, such as albendazole (ABZ), fenbendazole (FBZ), triclabendazole (TRBZ), or sulphoxides thereof, flubendazole (FLZ), mebendazole (MBZ), oxibe...
|
|
WO/2017/021178A1 |
The present invention concerns novel fused pyrimidinone and triazinone derivatives of formula (I), their process of preparation and their use as antifungal or antiparasitic agents.
|
|
WO/2017/017561A1 |
This invention relates to a formulation for use in the. topical treatment of diseases caused by pathogen micro- organisms and/or parasites in animals, comprising sodium dodecyl sulphate, 2, 2, 2-trichloroacetic acid and a stable colloida...
|
|
WO/2017/017091A1 |
The invention relates to a veterinary pharmaceutical composition comprising a combination of fipronil, selamectin and praziquantel in an acceptable pharmaceutical vehicle.
|
|
WO/2017/017021A1 |
The invention relates to novel veterinary compositions comprising an effective amount of a neonicotinoid compound and an effective amount of a N-arylpyrazole compound. The invention also relates to the use of such compositions for contro...
|
|
WO/2017/015471A1 |
A formulation for an eye treatment includes a photosensitizer and a permeability enhancing composition. The permeability enhancing composition includes one or more permeability enhancers. The permeability enhancing composition has a hydr...
|
|
WO/2017/015600A1 |
Methods are disclosed herein for at least one of (i) substantially reducing Plasmodium and/or oocyst development, (ii) substantially reducing mating success, (iii) substantially abolishing egg development after blood feeding, (iv) substa...
|
|
WO/2017/008101A1 |
An aminopeptidase inhibitor compound comprising a biaryl, hydroxamic acid based core of formula: wherein X is a 5 or 6-membered ring, and including pharmaceutically acceptable salts and solvates thereof.
|
|
WO/2017/009852A1 |
A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of anti-third party cells having a central memory T-lymphocy...
|
|
WO/2017/009219A1 |
This invention relates to a method of controlling the spread of dirofilariosis, such as for example heartworm, by administering to at least one non-human animal infested with filarioid nematodes such as Dirofilaria spp or susceptible to ...
|
|
WO/2017/009773A1 |
The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the prep...
|
|
WO/2017/009853A1 |
An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface recepto...
|
|
WO2017010858A1 |
The invention relates to an insecticide composition based on natural extracts for the control and/or elimination of ticks in livestock and/or in domestic animals, characterised by comprising: a) 50 to 65% Heliopsis logipes extract; b) 5 ...
|
|
WO/2017/001812A1 |
This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment o...
|
|
WO/2016/207402A1 |
The present invention provides a protein comprising a mutated LAIR-1 fragment, which broadly binds to erythrocytes infected with Plasmodium falciparum. The protein comprising the mutated LAIR-1 fragment may be useful in the prevention an...
|
|
WO/2016/207234A1 |
For the prevention of parasite infestation of animals, an isoxazoline can be administered by drinking water route. However the inventors have found that when the drinking water is sanitized, for instance by using hypochlorite, the isoxaz...
|
|
WO/2016/209635A1 |
The present invention provides Formula (1 ) compounds that are gamma-carbolines, Formula (1) wherein R1 a, R1 b, R1 c, R1d, R2, R3, and "— " are as defined herein; veterinary acceptable salts thereof, and stereoisomers thereof, which a...
|
|
WO/2016/201528A1 |
Provided are methods for preventing and/or treating inflammation and/or cancer in a subject by administration of an isolated EgKI-1 protein. Isolated EgKI-1 proteins, including nucleic acids encoding same, and an antibody raised against ...
|
|
WO/2016/198611A1 |
The present invention relates to N-(thio)acylimino compounds of formula (I) wherein the variables are as defined in the claims and the description, and the stereoisomers, tautomers and salts thereof. The invention further relates to agri...
|
|
WO/2016/197190A1 |
In one aspect, the present invention relates to the crystal structure of Plasmodium vivax plasmepsin V in complex with an inhibitor, and to methods of using the crystal structure and related structural information to identify, design and...
|
|
WO/2016/201219A1 |
The disclosure relates to compositions and methods for the treatment of fungal, bacterial, and parasitic infections and inhibition of fungal, bacterial, and parasitic growth. In particular, such compositions include dihydrofolate reducta...
|
